




Supplementary Fig. 1: Anti-Nuclear Antibody (ANA) staining in University of Pennsylvania COVID-19 patient cohort. **a.** IgG ANA indirect immunofluorescence results at a screening titer of 1:80, with positives confirmed at 1:160. Pie chart shows patient numbers (n=73 total), color coded by strength of staining and pattern. **b.** Analysis of ANA data in paired samples obtained on 21 patients showing the number of patients whose ANAs change over time. **d.** Images of positive ANAs from individual subjects, showing diffuse (left), nucleolar (middle) and speckled (right) staining patterns. Of note, UP01 was also weakly positive for dsDNA antibodies.



Supplementary Fig. 2: IgG ELISAs of virus and autoantigen-binding. Binding of IgG antibodies to SARS-CoV-2 receptor binding domain (RBD), nucleocapsid, and autoantigens (double stranded DNA (dsDNA), myeloperoxidase (MPO) and proteinase 3 (PR3)). Each symbol represents a patient (N=73). For subjects in which there were two or more time points, the D7 time point was chosen except for subject UP68, in whom the D14 time point was chosen. UP01 had a weakly positive dsDNA result. UP43 was positive for PR3.

Supplementary Fig. 3: Heatmap of MFI corresponding to Figure 1.






Supplementary Fig. 4: Validation in Kaiser Permanente cohort. Standard deviation heatmap depicting serum IgG antibodies discovered using a first generation 26-plex bead-based protein array containing the indicated autoantigens (y-axis). Autoantigens are grouped based on disease (scleroderma, SLE/Sjögren's, primary biliary cirrhosis (PBC)/thyroid, nucleosomes, and antigens associated with tissue inflammation). COVID-19 patients from Kaiser Permanente (left panel, n=48). HC (n=10, middle panel), and 7 prototype autoimmune disorders (right panel) are shown. Colors indicate autoantibodies whose MFI measurements are >5 SD (red), <5 or >3 SD (pink) or <3 SD (black) above the average MFI for HC. MFIs <5,000 were excluded.


COVID-19

Healthy Control

Prototype Autoimmune



- SU01 D0
- SU01 D14
- SU02 D30
- SU02 D60
- SU03 D0
- SU03 D7
- SU04 D0
- SU04 D30
- SU05 V2
- SU05 V3
- SU06 V1
- SU06 V2
- SU07 V2
- SU07 V3
- SU08 V1
- SU08 V2
- SU09 V2
- SU09 V3
- SU10 V2
- SU10 V4
- UP50 D0
- UP50 D7
- UP51 D0
- UP51 D7
- UP52 D0
- UP52 D7
- UP53 D0
- UP53 D7
- UP54 D0
- UP54 D7
- UP55 D0
- UP55 D7
- UP56 D0
- UP56 D7
- UP57 D0
- UP57 D7
- UP58 D0
- UP58 D7
- UP59 D0
- UP59 D7
- UP60 D0
- UP60 D7
- UP61 D0
- UP61 D7
- UP63 D0
- UP63 D7
- UP64 D0
- UP64 D7
- UP65 D0
- UP65 D7
- UP66 D0
- UP66 D7
- UP67 D0
- UP67 D7
- UP68 D0
- UP68 D14
- UP69 D0
- UP69 D7
- UP70 D0
- UP70 D7
- UP70 D21
- UP71 D0
- UP71 D7
- UP71 D14
- UMR01 D14
- UMR01 D60
- UMR02 D16
- UMR02 D29
- UMR03 D9
- UMR03 D26
- UMR04 D11
- UMR04 D16
- UMR05 D10
- UMR05 D47
- UMR06 D16
- UMR06 D52
- UMR07 D2
- UMR07 D39
- UMR08 D13
- UMR08 D20
- UMR09 D3
- UMR09 D21
- UMR10 D20
- UMR10 D29
- UMR11 D19
- UMR11 D47
- UMR12 D6
- UMR12 D15
- UMR13 D1
- UMR13 D3
- UMR14 D18
- UMR14 D40
- UMR15 D3
- UMR15 D40
- UMR16 D6
- UMR16 D8
- UMR20 D6
- UMR20 D14



- HC16
- HC17
- HC18
- HC19
- HC20
- HC21
- HC22
- HC23
- HC24
- HC25
- HC26
- HC27
- HC28
- HC29
- HC30
- HC31

- Scl-70
- Mitochondrial RNP
- Centromere
- Thyroglobulin (TG)
- Ro/SSA
- La/SSB
- Histone
- APS-1
- APS-1
- APS-1
- PAP (GM-CSF)
- AMI (IFN-gamma)
- AMI (IFN-gamma)
- AMI (IFN-gamma)

Scleroderma

Myositis/Overlap Syndromes

SLE/Sjögren's

GI/Endocrine

DNA-Associated

Inflammation/Stress


Interferons




Interleukins

Other Cytokines





Supplementary Fig. 5: Evolution of IgG autoantibody development over time in hospitalized COVID-19 patients. **a.** Heatmap using the same 53-plex bead-based protein array presented in Figure 1, containing the indicated autoantigens (x-axis). Autoantigens are grouped based on disease (scleroderma, myositis and overlap syndromes such as MCTD, SLE/Sjögren's, gastrointestinal and endocrine disorders), DNA-associated antigens, and antigens associated with tissue inflammation or stress responses. COVID-19 patients (top panel, n=98 longitudinal COVID-19 samples, including 92 paired samples from 46 subjects and two subjects who had three available timepoints each, subject UP70 and UP71). HC (n=16, middle panel), and 8 prototype autoimmune disorders (bottom panel) are shown. **b.** Heatmap using a 41-plex array of cytokines, chemokines, growth factors, and receptors. The same samples in Panel A were also analyzed for ACA. Cytokines are grouped on the x-axis by category (interferons, interleukins, and other cytokines/growth factors/receptors). Prototype samples from patients with immunodeficiency disorders include three patients with APS1, one patient with PAP, and three patients with AMI. Colors correspond to the MFI values shown at far right.

Supplementary Fig. 6: Standard deviation heatmap of MFI corresponding to Figure 3.






Supplementary Fig. 7: Number of antibodies in 21 subjects with paired D0 and D7 time point data, stratified by reactivity category. **a.** Heatmap of individual subjects. Rows denote subjects and time points in days (day 0, D0 and day 7, D7). Columns denote Autoantibodies (AutoAb) and Anti-Cytokine Antibodies (ACA). Antibodies are above 5 standard deviations compared to pooled healthy controls (5 SD) or between 3 and 5 standard deviations (3 SD). White cells indicate 0 antibodies. **b.** Antibody counts at D0 and D7 stratified by antibody category. Autoantibody (AutoAb, blue) and anti-cytokine antibody (ACA, yellow) counts are shown for the same 21 subjects at Day 0, (left) and Day 7 (right). Counts were based on antibodies that were present at levels between 3 and 5 SD above the average MFI for healthy control samples. **c.** Antibodies per subject shown for different antibody level cut-offs. 5 SD = > 5 SD above the average MFI for the HC group; 3 SD = >3 and <5 SD above the average MFI for HC; In SUM, the 5 and 3 SD data were separately added for each individual. This category represents all antibodies detected at 3 SD or higher. AutoAb = autoantibodies; ACA = anti-cytokine antibodies. Horizontal red lines indicate medians. Each symbol represents a subject. P values are computed using the Wilcoxon paired rank sum test. Only D7 AutoAb vs. D7 ACA were significant ($p < 0.05$) for the 3 SD and SUM antibody levels.



Supplementary Fig. 8: Comparison between ELISA and bead-based assays. a and b. Correlation analysis between ELISA and multiplex bead data. All samples (including multiple time points from individual subjects) were included in the correlation analysis (N=57 samples from 35 individuals). Each symbol represents a sample with the mean fluorescence intensity (MFI) vs. the optical density (OD). Spearman correlations were computed with two-tailed p-values. **c and d.** Two representative line plots for 21 patients with paired samples at D0 and D7. IgG antibodies increased over time for RBD ($p=0.042$, Wilcoxon rank sum test) but did not change over time for Nucleocapsid ($p=0.73$, NS, Wilcoxon rank sum test).

Autoantigens

Viral Antigens



Supplementary Fig. 9: MFI bar plots for individual autoantigens and viral antigens for the four patients with one or more newly triggered autoantibodies, corresponding to Figure 5. Error bars represent one standard deviation of the MFI for sample replicates.